Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced a significant $185 million private placement financing. The private ...

Tectonic Therapeutic (NASDAQ:TECX) has announced a ~$185M capital raise to fund the clinical development of its drug candidates. Pursuant to the terms of the securities purchase agreement, at the ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

Tectonic Therapeutic (NASDAQ:TECX – Free Report) had its price objective raised by Wells Fargo & Company from $79.00 to $112.00 in a research report report published on Friday morning,Benzinga reports ...

What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report)’s share price traded up 6.7% on Friday after Wells Fargo & Company raised their price target on the stock from $79.00 to $112.00. Wells Fargo & ...

Detailed price information for TD Global Tech Leaders CAD Hdg Idx ETF (TECX-T) from The Globe and Mail including charting and trades.

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fell 0.25% to 19,583.83. The S&P 500 also ...